Kubota Pharmaceutical will sell specially designed glasses dubbed Kubota Glass, which it claims are able to reverse the effects of myopia.
The glasses shine tiny lights at the retina to simulate short-distance blurring, forcing the user to look further ahead and in doing so taking the pressure of the axial deformation of eyeballs.
Long-term testing is still required to gauge how effective Kubota Glass is at this in detail, but studies so far suggest that they are at least effective at curbing the progression of myopia.
Kubota Glass has been approved as a medical device in Taiwan and the USA.
Kubota Pharmaceutical charges 770,000 yen for a pair of Kubota Glass while offering a 100-percent satisfaction guarantee.
According to 2009 research conducted by Japan's Ministry of Education, Culture, Sports, Science, and Technology, around 25% of first-graders had less than perfect eyesight, with the percentage rising to 50% among sixth-graders.


AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
South Korea Central Bank Holds Interest Rates Steady Amid Inflation Concerns
Nikkei Hits Record High as AI Chip Stocks Power Japan Market Rally
Canada and Germany Advance Major LNG Supply Partnership
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand
US Launches New Trade Investigation Into Vietnam Over Intellectual Property Concerns
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions
ECB’s Philip Lane Warns Middle East Conflict Could Keep Inflation Elevated
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix
Dow Hits Record High as Healthcare and Consumer Stocks Lead Wall Street Rally
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand
The four types of dementia most people don’t know exist
European Stocks Rise as AI Optimism Offsets U.S.-Iran Tensions
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding 



